Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis

Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis

IntroductionRoxadustat treatment in PD patients is equivalent to ESAs in increasing hemoglobin (Hb). But blood pressure, cardiovascular parameters, cardio-cerebrovascular complications and prognosis in the two groups before and after treatment has not been sufficiently discussed.MethodsSixty PD pati...

Full description

Bibliographic Details
Main Authors:	Shuiqin Cheng, Tingting Zhou, Le Yu, Zhihong Zhang, Yunmin Chen, Man Zhang, Jingjing Cui, Wenxin Yu, Jian Zhou, Yusheng Yu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Medicine
Subjects:	roxadustat recombinant human erythropoietin peritoneal dialysis blood pressure cardio-cerebrovascular complications
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1166024/full

Similar Items

Effects of Roxadustat on Erythropoietin Production in the Rat Body
by: Yukiko Yasuoka, et al.
Published: (2022-02-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
by: Yangyang Zhang, et al.
Published: (2023-10-01)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
by: Tong Wu, et al.
Published: (2022-12-01)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
by: Keiji Hirai, et al.
Published: (2021-07-01)

Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial
by: Yan-Pei Hou, et al.
Published: (2022-02-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
by: Qiaoqiao Zhou, et al.
Published: (2023-12-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
by: Zhipeng Yan, et al.
Published: (2020-08-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
by: Yaling Zhang, et al.
Published: (2021-01-01)

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1<sup>+</sup> Cells
by: Aline Jatho, et al.
Published: (2022-02-01)

Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials
by: Ting Chen, et al.
Published: (2022-11-01)

Resistance of dialyzed patients to erythropoietin
by: Michelle Teodoro Alves, et al.
Published: (2015-06-01)

Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis
by: Yan-Pei Hou, et al.
Published: (2022-11-01)

Plasma erythropoietin level and heart failure in patients undergoing peritoneal dialysis: a cross-sectional study
by: Kohsuke Terada, et al.
Published: (2021-01-01)

Protective effects of catalpol on cardio-cerebrovascular diseases: A comprehensive review
by: Zixi Zhang, et al.
Published: (2023-10-01)

Derivation and Validation of Risk Scores to Predict Cerebrovascular Mortality Among Incident Peritoneal Dialysis Patients
by: Xiaoxue Zhang, et al.
Published: (2018-07-01)

Characteristics and mortality of patients with and without cardio-renal syndrome treated by peritoneal dialysis in France
by: Gabrielle Duneau, et al.
Published: (2022-12-01)

Roxadustat reduced the risk of perioperative complication arising from the treatment of cardiac paraganglioma: A case report
by: Dong Wang, et al.
Published: (2023-09-01)

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study
by: Shohei Kaneko, et al.
Published: (2020-01-01)

Associations between ultrafine particles（UFPs） exposure and occurrence and mortality of cardio-cerebrovascular diseases in Minhang District， Shanghai： a time-series analysis
by: GU Yiqin, et al.
Published: (2022-05-01)

Baseline Soluble Anti-erythropoietin Antibody Level Is an Independent Associated Factor for Follow-Up Erythropoietin Demand in Maintenance Dialysis Patients With End-Stage Renal Disease: A Prospective Cohort Study
by: Ying Zhang, et al.
Published: (2020-04-01)

Ferroptosis: New Dawn for Overcoming the Cardio-Cerebrovascular Diseases
by: Meng-Yi Luo, et al.
Published: (2021-11-01)

Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases
by: Mohan Li, et al.
Published: (2023-05-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

Artificial Intelligence: A Shifting Paradigm in Cardio-Cerebrovascular Medicine
by: Vida Abedi, et al.
Published: (2021-12-01)

Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin
by: Xiaowei Yang, et al.
Published: (2021-01-01)

Successful treatment of peritoneal dialysis for two patients with refractory nephrotic syndrome and acute kidney injury: a case report
by: Le Yu, et al.
Published: (2023-10-01)

Clinical impact of medication adherence on 10‐year cardio‐cerebrovascular mortality in newly diagnosed hypertensive patients
by: Cho‐Long Kim, et al.
Published: (2021-09-01)

Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes
by: Dabei Fan, et al.
Published: (2018-05-01)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
by: Keiji Hirai, et al.
Published: (2023-02-01)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis
by: Wen-Yi Li, et al.
Published: (2008-11-01)

Elevated Lipoprotein(a) Levels are Associated with Arterial Stiffness Measured by Cardio-Ankle Vascular Index in Patients Undergoing Peritoneal Dialysis
by: Po-Yu Huang, et al.
Published: (2023-11-01)

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude
by: Guo Q, et al.
Published: (2023-01-01)

Research Advances in Cardio-Cerebrovascular Diseases of Ligusticum chuanxiong Hort.
by: Dan Li, et al.
Published: (2022-01-01)

Association Between the Polymorphism of Angiotensin-Converting Enzyme Gene and Interleukin-1 Beta Gene and the Response to Erythropoietin Therapy in Dialysis Patients with Anemia
by: Dzekova-Vidimliski P, et al.
Published: (2024-03-01)